Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11)

Upper Tract Urothelial Carcinoma Clinical Trial

Official title:

Phase I Study of WST11 Phototherapy for Upper Tract Urothelial Carcinoma

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03617003
• Other study ID #: 18-140
• Status: Active, not recruiting
• Phase: Phase 1
• Start date: August 1, 2018
• Est. completion date: December 2, 2024

Study information

• Verified date: December 2023
• Source: Memorial Sloan Kettering Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to test the safety of a combination of the study drug called WST11 and PDT. Photodynamic therapy (PDT) is a type of ablation therapy (treatment which destroys tumor cells) which has been previously approved for the treatment of patients with other cancers. It works by using a drug that is given through the vein and then is activated in the tumor by light administered during endoscopy, which results in destruction of the cancer cells.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 30
• Est. completion date: December 2, 2024
• Est. primary completion date: December 2, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age 18 or older

• Confirmed tissue diagnosis of urothelial carcinoma involving the ureter and/or renal pelvis with pathology reviewed at MSKCC

• Residual or recurrent cancer following prior endoscopic treatment

• Ineligible, unwilling or refusing to undergo surgical management by resection of involved kidney or ureter.

• Karnofsky performance status = 50%

• Patients with existing ureteral obstruction and/or existing ureteral stent will be permitted. Demonstration of the site and degree of obstruction must be documented by retrograde pyelography at the time of initial and follow up endoscopic procedures within 60 days.

• Patients should not have received any systemic therapy (including chemotherapy, biologic therapy or immunotherapy) =4 weeks prior to treatment

• Patients on prophylactic or full-dose anticoagulation are eligible, provided the treating physician believes it is safe to temporarily withhold anticoagulation (see Section 9.2)

• Adequate organ function defined at baseline as:

• ANC =1,000/ µL

• Platelets =75,000/ µL

• Hb =9 g/dl

• INR =1.5 (except for patients who are on full-dose warfarin)

• Calculated creatinine clearance =40 ml/min (using Cockcroft-Gault method)

• Total serum bilirubin =1.5 mg/dL

• AST/ALT =5× upper limit of normal

• Able to provide written informed consent

Exclusion Criteria:

• Pregnant or breast-feeding women. Women of childbearing potential (WOCBP) must undergo a negative pregnancy test (either serum or urine) prior to study entry. Both sexes must use contraception while on study. WOCBP include:

• Any woman who has experienced menarche and who has not undergone surgical sterilization (hysterectomy, bilateral tubal ligation or oophorectomy) or who is not post-menopausal (defined as amenorrheic =12 consecutive months)

• Women on hormone replacement therapy with documented serum follicle stimulating hormone level > 35 mIU/ml

• Women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as intrauterine device or barrier methods to prevent pregnancy or are practicing abstinence or where the partner is sterile

• T4 tumors with involvement of the bowel or major blood vessels • Any other medical or psychiatric comorbidities, including decompensated heart failure, unstable angina or coronary artery disease or severe pulmonary disease that, in the opinion of the study investigator, would make the patient a poor candidate for the study

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Upper Tract Urothelial Carcinoma

Intervention

Drug:
• WST11 mediated vascular targeted phototherapy (VTP)
All patients will receive intravenous administration of WST11 at a dose of 4 mg/kg, infused over 10 minutes while patients are under anesthesia during their endoscopy procedure, followed by immediate laser light application.

Procedure:
• Endoscopy
Endoscopy of the bladder

Locations

Country	Name	City	State
United States	Memorial Sloan Kettering Cancer Center	New York	New York

Sponsors (1)

Lead Sponsor	Collaborator
Memorial Sloan Kettering Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated laser fluence rate	The MTD will be defined as the dose whose toxicity rate does not exceed an acceptable threshold of toxicity 20%.in this study, we shall start at 100mW/cm and will carefully escalate the dose to a maximum of 200 mW/cm.	2 years

External Links

•   Memorial Sloan Kettering Cancer Center